[Multiple myeloma and intravenous immunoglobulins].
Feugier
P
P
Service d'hématologie adulte, CHU Brabois, allée du Morvan, 54511 Vandoeuvre, France. p.feugier@chu-nancy.fr
Tomowiak
C
C
Daguindau
N
N
Perrot
A
A
D000361:Agammaglobulinemia / Q000150:complications; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D007239:Infections / Q000150:complications; D008297:Male; D015337:Multicenter Studies as Topic; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D011446:Prospective Studies; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D012189:Retrospective Studies; D013997:Time Factors
D000970:Antineoplastic Agents; D001897:Boronic Acids; D016756:Immunoglobulins, Intravenous; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib